Status:
COMPLETED
Rollover Protocol for Subjects Who Have Responded on Study 4218s - A Phase 2 Study
Lead Sponsor:
Mateon Therapeutics
Conditions:
Neuroendocrine Tumors
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
Subjects achieving a clinical response in study OX4218s with a biomarker reduction or symptom response are eligible to enroll in this rollover study to continue once every three weeks fosbretabulin in...
Detailed Description
Subjects enrolled in the PNET/GI-NET study OX4218s received weekly dosing with fosbretabulin for up to 3 cycles or approximately 9 weeks. Subjects achieving a clinical response with a biomarker reduct...
Eligibility Criteria
Inclusion
- Subject has been treated in the OXiGENE-sponsored Phase 2 study OX4218s
Exclusion
- Subject has not received fosbretabulin treatment in the study OX4218s
Key Trial Info
Start Date :
December 1 2014
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
August 1 2016
Estimated Enrollment :
7 Patients enrolled
Trial Details
Trial ID
NCT02279602
Start Date
December 1 2014
End Date
August 1 2016
Last Update
April 17 2018
Active Locations (5)
Enter a location and click search to find clinical trials sorted by distance.
1
Stanford University School of Medicine
Stanford, California, United States, 94305
2
Markey Cancer Center, Clinical Research Office
Lexington, Kentucky, United States, 40356
3
Montefiore
The Bronx, New York, United States, 10467
4
Duke University Medical Center
Durham, North Carolina, United States, 27710